Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: ORBE II study

Table 1 Baseline demographic characteristics of the study population

Parameters	Total N = 204
Age (years), mean (SD)	56.4 (12.4)
Women, n/N (%)	127/204 (62.3%)
BMI (Kg/m²), mean (SD)^a	28.1 (6.3)
Obese (BMI ≥ 30 Kg/m²), n/N (%)	54/188 (28.7%)
Age at asthma onset (years), mean (SD)	34.4 (16.4)
Asthma duration (years), mean (SD)	15.1 (12.7)
Allergic asthma, n/N (%)^b	68/204 (33.3%)
Smoking history, n/N (%)^c
Non-smoker	128/203 (63.1%)
Former smoker	69/203 (34%)
Smoker	6/203 (3%)
Comorbidities, n/N (%)	191/204 (93.6%)
CRSwNP	75/204 (36.8%)
Gastroesophageal reflux	42/204 (20.6%)
Dyslipidaemia	36/204 (17.6%)
Osteoporosis	32/204 (15.7%)
Arterial hypertension	32/204 (15.7%)
Sleep apnoea syndrome	26/204 (12.7%)
Type II diabetes mellitus	18/204 (8.8%)
Depression	17/204 (8.3%)
COPD	14/204 (6.9%)
Anxiety	13/204 (6.4%)
Hypothyroidism	12/204 (5.9%)
Cataracts	6/204 (2.9%)

Due to the nature of this real-world study, sample sizes vary due to missing/ unavailable/ not valid
^aData missing from 16 patients; ^bAs determined by the investigator; ^cData missing from 1 patient
All percentages were calculated over the total of patients with valid data
BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRSwNP, chronic rhinosinusitis with nasal polyposis; SD, standard deviation

ISSN: 1465-993X